• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Gala Therapeutics launches RheOx chronic bronchitis trial

Gala Therapeutics launches RheOx chronic bronchitis trial

November 5, 2018 By Fink Densford

Gala Therapeutics

Gala Therapeutics said today that it launched an early feasibility study of its RheOx system for treating chronic bronchitis, and that the first two patients in the trial have already been enrolled.

Initial patient enrollment took place at the University of Pittsburgh Medical Center, with RheOx bronchial rheoplasty procedures performed by Dr. Frank Sciurba and Roy Semaan, the Menlo Park, Calif.-based company said.

“We are pleased to partner with Gala in treating the first US patients and thus continuing the contribution of UPMC as a leader in the development of novel devices for our patients with COPD. RheOx offers a potential solution for an unmet need for so many patients who suffer with the persistent symptoms of chronic bronchitis, representing a personalized therapy for our patients with one type of COPD,” UPMC Emphysema/COPD Research Center director Dr. Sciurba said in a prepared statement.

The RheOx system is an electrosurgical platform intended to target abnormal, mucus-producing cells in the airways.

The system includes a catheter, designed to be used alongside an endoscope, to deliver short bursts of electrical energy to the airway walls. The procedure is intended to replace the abnormal cells with new cells that produce less mucus, Gala Therapeutics said.

The trial aims to enroll 15 subjects at five U.S. sites, with the procedures performed in two treatment sessions. The first session treats the right lung airways and a second procedure a month later treats the left lung airways.

The primary endpoint for the trial is safety, while secondary endpoints include changes in quality of life as measured by the Saint George’s Respiratory Questionnaire and COPD Assessment Test, as well as pulmonary function testing and CT scans, the company said.

“Treatment of the first subjects in the United States through the novel EFS pathway is a significant milestone for Gala Therapeutics. We look forward to enrolling additional patients at new US clinical sites in the coming weeks,” Gala founder & CEO Dr. Jonathan Waldstreicher said in a press release.

In July, Gala Therapeutics said that it won FDA investigational device exemption approval to conduct an early feasibility study of its RheOx system designed to treat individuals with chronic bronchitis.

Filed Under: Clinical Trials, Respiratory Tagged With: galatherapeutics

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy